藥碼
NEU01
藥名
Rotigotine 經皮貼片 藍 8 mg
英文商品名
Neupro 經皮貼片 藍 8 mg
中文商品名
紐普洛穿皮貼片劑8毫克/24小時
螢幕名
Neupro 經皮貼片 藍 8 mg
劑型
Tap
規格
Rotigotine 18mg/patch
成分
藥理分類
Antiparkinsonian-Dopamine receptor agonists
健保碼
BC24936326
ATC碼
適應症
Parkinson's disease.
Restless legs syndrome (Moderate to Severe).
#仿單變更2021
Restless legs syndrome (Moderate to Severe).
#仿單變更2021
藥理
Rotigotine is a non-ergoline dopamine receptor agonist. The precise mechanisms of action in the treatment of Parkinson disease and restless legs syndrome are unknown but are thought to be related to rotigotine's ability to stimulate dopamine receptors. In the treatment of Parkinson disease, rotigotine is thought to stimulate dopamine receptors within the caudate-putamen in the brain.
藥動學
Distribution:
Vd: 84 L/kg
Metabolism:
Hepatic; extensive via N-dealkylation and conjugation, catalyzed by multiple CYP isoenzymes, sulfotransferases and 2 UDP-glucuronosyltransferases
Excretion:
Renal: approximately 71%
Dialyzable: no
Elimination Half Life:
3 hours initially, then 5 to 7 hours (biphasic) .
Vd: 84 L/kg
Metabolism:
Hepatic; extensive via N-dealkylation and conjugation, catalyzed by multiple CYP isoenzymes, sulfotransferases and 2 UDP-glucuronosyltransferases
Excretion:
Renal: approximately 71%
Dialyzable: no
Elimination Half Life:
3 hours initially, then 5 to 7 hours (biphasic) .
禁忌症
Hypersensitivity to rotigotine or any component of the product.
懷孕分類
C (FDA)B3 (AUS)
哺乳分類
Milk effects are possible.(MDX)
副作用
Cardiovascular: Orthostatic hypotension (Parkinson disease, 16% to 32%; restless legs syndrome, 8% to 13% ), Peripheral edema (2% to 9% )
Dermatologic: Application site reaction (19% to 43% ), Diaphoresis (1% to 11% )
Gastrointestinal: Loss of appetite (2% to 9% ), Nausea (Parkinson disease, 28% to 48%; restless legs syndrome, 15% to 23% ), Vomiting (Parkinson disease, 10% to 20%; restless legs syndrome, 2% to 4% ), Xerostomia (3% to 7% )
Neurologic: Dizziness (Parkinson disease, 14% to 23%; restless legs syndrome, 5% to 9% ), Dyskinesia (14% ), Headache (10% to 21% ), Sleep disorder (2% to 14% ), Somnolence (5% to 32%; sudden onset of sleep, up to 2% )
Cardiovascular: Atrioventricular block, First degree (3% ), Syncope
Psychiatric: Compulsive behavior, Hallucinations (Up to 7% ), Impulse control disorder.
increased creatine phosphokinase in blood specimen <2021/4/19>
劑量和給藥方法
Parkinson's disease:
Early-stage: Initial, 2 mg/24 hours TRANSDERMALLY; titration, 2 mg/24 hours TRANSDERMALLY weekly; minimum effective dose, 4 mg/24 hours TRANSDERMALLY; MAX, 6 mg/24 hours TRANSDERMALLY
Advanced-stage: Initial, 4 mg/24 hours TRANSDERMALLY; titration, 2 mg/24 hours TRANSDERMALLY weekly; MAX, 8 mg/24 hours TRANSDERMALLY
Restless legs syndrome (Moderate to Severe):
Initial, 1 mg/24 hours TRANSDERMALLY; titration, 1 mg/24 hours TRANSDERMALLY weekly; minimum effective dose, 1 mg/24 hours TRANSDERMALLY; MAX, 3 mg/24 hours TRANSDERMALLY .
Early-stage: Initial, 2 mg/24 hours TRANSDERMALLY; titration, 2 mg/24 hours TRANSDERMALLY weekly; minimum effective dose, 4 mg/24 hours TRANSDERMALLY; MAX, 6 mg/24 hours TRANSDERMALLY
Advanced-stage: Initial, 4 mg/24 hours TRANSDERMALLY; titration, 2 mg/24 hours TRANSDERMALLY weekly; MAX, 8 mg/24 hours TRANSDERMALLY
Restless legs syndrome (Moderate to Severe):
Initial, 1 mg/24 hours TRANSDERMALLY; titration, 1 mg/24 hours TRANSDERMALLY weekly; minimum effective dose, 1 mg/24 hours TRANSDERMALLY; MAX, 3 mg/24 hours TRANSDERMALLY .
小兒調整劑量
Safety and effectiveness have not been established in children .
腎功能調整劑量
肝功能調整劑量
安定性
藥袋資訊
臨床用途
治療帕金森氏症
主要副作用
嗜睡、眩暈、頭痛、噁心、嘔吐、腹痛、便秘、皮膚刺激
泡製方法
儲存方式
請置於 15-30℃ 乾燥處儲存
注意事項
其他說明
藥局 P2 | 藥庫 外用/水D13 | <一盒28片>
藥品外觀
顏色
形狀
剝痕
N
標記1
標記2
其他
健保藥價
91
自費價
121.03
仿單
資料庫
健保給付規定